Author

O. Olén

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Upadacitinib Is Associated with the Lowest Risk of Treatment Failure Among Advanced Therapies for Ulcerative Colitis: A Real-World Administrative Claims Study.

BACKGROUND AND AIMS We compared the real-world effectiveness of advanced therapies (AT) in patients with ulcerative colitis (UC). METHODS Using the OptumLabs® Data Warehouse, a nationally representative US administrative claims database, we identified patients with UC initiating infliximab, adalimumab, vedolizumab, u...

M. Hupé, D. Ahuja, Kuan-Hung Yeh et al. · Clinical Gastroenterology an... · 0 citations

Aug 2026

Cancer Risk with Advanced Therapies in Patients with Inflammatory Bowel Diseases: An Administrative Claims-based Study.

BACKGROUND AND AIMS We conducted a retrospective cohort study comparing the risk of cancer in patients with inflammatory bowel diseases (IBD) initiating advanced therapies (ATs). METHODS Using an administrative claims database (OptumLabs® Data Warehouse), we identified patients with IBD with no prior history of cance...

D. Ahuja, Kuan-Hung Yeh, Soo-kyung Park et al. · Clinical Gastroenterology an... · 0 citations

Open access Sep 2026

Impact of Family History on Colorectal Cancer Risk in Inflammatory Bowel Disease and in Matched General Population Comparators.

Family history of CRC increased CRC incidence similarly in IBD and matched comparators, with the greatest increase in individuals with multiple affected relatives, raising the question if surveillance strategies should instead prioritize patients with multiple affected relatives.

Å. H. Everhov, Kári Kristjánsson, J. Ludvigsson et al. · Gastroenterology · 0 citations